TherapeuticsMD
TXMD
143 hedge funds and large institutions have $981M invested in TherapeuticsMD in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 20 closing their positions.
83% more call options, than puts
Call options by funds: $7.21M | Put options by funds: $3.94M
24% more capital invested
Capital invested by funds: $791M → $981M (+$190M)
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
0% more funds holding
Funds holding: 143 → 143 (0)
0.05% less ownership
Funds ownership: 1.5% → 1.45% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.1M |
| 2 |
Public Employees Retirement Association of Colorado
Denver,
Colorado
|
+$6.3M |
| 3 |
BlackRock
New York
|
+$3.72M |
| 4 |
First Eagle Investment Management
New York
|
+$3.12M |
| 5 |
JP Morgan Chase
New York
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$53.8M |
| 2 |
Bank of New York Mellon
New York
|
-$11.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.64M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.71M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$3.39M |
TXMD Hedge Fund Activity: Q2 2018 in Review
143 of the 4,384 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2018, worth a combined $981M — up 24% from $791M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TXMD positions and 20 closed out — a net gain of 1 holder — while 50 added to existing stakes and 44 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $39.1M. The largest seller was Fidelity Investments, cutting an estimated $53.8M.
- 143 institutional investors held TherapeuticsMD (TXMD) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $981M of TherapeuticsMD stock for Q2 2018, up 24% quarter-over-quarter.
- 21 funds opened new TherapeuticsMD positions in Q2 2018 and 20 closed out, a net change of +1 holder.
- The largest TherapeuticsMD buyer in Q2 2018 was T. Rowe Price Associates, an estimated $39.1M added.
- The largest TherapeuticsMD seller in Q2 2018 was Fidelity Investments, an estimated $53.8M sold.
Based on aggregated 13F filings for Q2 2018.